OssDsign AB
STO:OSSD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6
10.88
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
OssDsign AB
Cost of Revenue
OssDsign AB
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
OssDsign AB
STO:OSSD
|
Cost of Revenue
-kr28.5m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Cost of Revenue
-kr192.1m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-26%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Cost of Revenue
-kr5.1m
|
CAGR 3-Years
23%
|
CAGR 5-Years
25%
|
CAGR 10-Years
12%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Cost of Revenue
-kr161.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Cost of Revenue
-€187.2m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Cost of Revenue
-kr1.1m
|
CAGR 3-Years
39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
OssDsign AB
Glance View
OssDsign AB is a holding company, which designs, manufactures, and sells implants and material technology for bone regeneration. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2019-05-24. The company aims at developing implantable products that respond to clinical challenges, with focus on bone healing. Its primary focus is skull surgery. The firm uses design solutions, material compositions and manufacturing processes mainly based on proprietary bioceramic technologies. The bioceramics it uses integrate with tissues and support bone ingrowth. OssDsign AB's main product is Craniomosaic, an implant for the repair of skull defects (cranioplasty). Along with it, the Company develops bioceramic implants for facial bone augmentation. The firm's customers include neurosurgeons, craniofacial and maxillofacial surgeons.
See Also
What is OssDsign AB's Cost of Revenue?
Cost of Revenue
-28.5m
SEK
Based on the financial report for Dec 31, 2023, OssDsign AB's Cost of Revenue amounts to -28.5m SEK.
What is OssDsign AB's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-48%
Over the last year, the Cost of Revenue growth was -30%. The average annual Cost of Revenue growth rates for OssDsign AB have been -48% over the past three years .
You don't have any saved screeners yet
